Lorna Hazell
Overview
Explore the profile of Lorna Hazell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klein K, Hazell L, Stolk P, Shakir S
Drug Saf
. 2019 Dec;
43(3):255-263.
PMID: 31872358
Introduction: Due to the complexity of biologics and the inherent challenges for manufacturing, it is important to know the specific brand name and batch number of suspected biologics in adverse...
2.
Phillips R, Hazell L, Sauzet O, Cornelius V
BMJ Open
. 2019 Mar;
9(2):e024537.
PMID: 30826796
Objective: To ascertain contemporary approaches to the collection, reporting and analysis of adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy outcome. Design: A review of clinical...
3.
Hazell L, Raschi E, De Ponti F, Thomas S, Salvo F, Ahlberg Helgee E, et al.
J Clin Pharmacol
. 2016 Dec;
57(5):558-572.
PMID: 28019033
A systematic review was performed to categorize the hERG (human ether-a-go-go-related gene) liability of antihistamines, antipsychotics, and anti-infectives and to compare it with current clinical risk of torsade de pointes...
4.
Raschi E, Poluzzi E, Salvo F, Koci A, Suling M, Antoniazzi S, et al.
Drug Saf
. 2015 Oct;
39(1):59-68.
PMID: 26446144
Introduction: Spontaneous reporting systems (SRSs) are pivotal for signal detection, especially for rare events with a high drug-attributable component, such as torsade de pointes (TdP). Use of different national SRSs...
5.
Margulis A, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman N, et al.
Clin Epidemiol
. 2014 Oct;
6:359-68.
PMID: 25336990
Background: The study objective was to compare the Newcastle-Ottawa Scale (NOS) and the RTI item bank (RTI-IB) and estimate interrater agreement using the RTI-IB within a systematic review on the...
6.
Varas-Lorenzo C, Margulis A, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, et al.
BMC Cardiovasc Disord
. 2014 Sep;
14:129.
PMID: 25260374
Background: Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summary of the effects of blood glucose-lowering drugs other than glitazones on the risk...
7.
Hazell L, Cornelius V, Hannaford P, Shakir S, Avery A
Drug Saf
. 2013 Feb;
36(3):199-206.
PMID: 23444232
Background: In 2005, spontaneous reporting of adverse drug reactions (ADRs) to the UK's Yellow Card Scheme (YCS) was extended to include patient reports. Here, we investigate the potential pharmacovigilance impact...
8.
Layton D, Hazell L, Shakir S
Drug Saf
. 2011 Nov;
34(12):e1-9.
PMID: 22077508
Prescription-Event Monitoring (PEM) is a well established postmarketing surveillance technique designed to monitor the overall safety of newly marketed medicines as used in real-life clinical practice, usually in cohorts of...
9.
McLernon D, Bond C, Hannaford P, Watson M, Lee A, Hazell L, et al.
Drug Saf
. 2010 Aug;
33(9):775-88.
PMID: 20701410
Background: In the UK, spontaneous reporting of suspected adverse drug reactions (ADRs) by healthcare professionals has been in operation since 1964 through the Yellow Card Scheme (YCS). From 2005, patients...
10.
Osborne V, Hazell L, Layton D, Shakir S
Drug Saf
. 2010 Feb;
33(3):213-21.
PMID: 20158285
Background: Intrinsa is a transdermal testosterone patch that is indicated for use in hypoactive sexual desire disorder (HSDD) in women who have undergone bilateral oophorectomy and hysterectomy (surgically-induced menopause) receiving...